Rivastigmine
Product Images NDC 16714-115

21 FDA label images from Northstar Rx Llc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 16714-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 01)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 01)
Chemical structure of rivastigmine, showing a benzene ring with multiple attached groups including methyl, ethyl, and amino functional groups. The diagram uses standard line and letter notation to represent atoms and bonds.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 02)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 02)
A cross-sectional diagram illustrating four distinct layers labeled Layer 1 through Layer 4 in a stacked arrangement, each represented by different shading patterns. The figure visually differentiates the layers but does not provide additional text or details about their specific composition or function.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 10)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 10)
A line graph showing Rivastigmine plasma concentration (ng/mL) over 24 hours for three dosage strengths: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The graph plots mean concentrations with error bars and illustrates concentration changes over time for each dose group.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 03)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 03)
A line graph depicting least square means (+/- SEM) change from baseline ADAS-Cog rating over 24 weeks of treatment. It compares clinical improvement and decline among four groups: 17.4 mg/24 hours (solid black line), 9.5 mg/24 hours (solid gray line), Capsules 6 mg BID (dotted gray line), and Placebo (solid dark gray line). The x-axis represents weeks during treatment (0, 16, 24), and the y-axis shows change in ADAS-Cog rating from -2.5 to 2, with clinical improvement above zero and decline below zero.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 04)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 04)
Bar chart showing the percentage of patients by ADCS-CGIC rating categories for different Rivastigmine treatments and placebo. Categories include Markedly Improved to Markedly Worse, with comparative data for 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg capsules BID, and placebo groups.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 05)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 05)
A line graph comparing the change from baseline in ADCS-IADL scores over 48 weeks for Rivastigmine Transdermal System at 13.3 mg/24 hr and 9.5 mg/24 hr doses, showing clinical improvement or decline. The graph includes error bars and indicates statistically significant differences at certain time points between the two doses.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 06)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 06)
A line graph comparing the ADAS-Cog change from baseline in LS means and SEM over 48 weeks of treatment for Rivastigmine Transdermal System at strengths 13.3 mg/24 hr and 9.5 mg/24 hr. The Y-axis represents clinical improvement and decline, while the X-axis shows weeks of treatment. The 13.3 mg/24 hr dose is marked with squares and shows less cognitive decline than the 9.5 mg/24 hr dose marked with circles.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 07)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 07)
A line graph comparing the least squares mean changes over 24 weeks of treatment for Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr. The Y-axis shows LS mean change with standard error, ranging from clinical decline to improvement. The 13.3 mg/24 hr dose shows lesser decline and statistical significance at weeks 16 and 24 versus the 4.6 mg/24 hr dose.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 08)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 08)
Line graph depicting the least squares mean change plus/minus standard errors over 24 weeks of treatment comparing Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr. The y-axis represents LS mean change with clinical improvement at the top and clinical decline at the bottom. The x-axis indicates weeks of treatment (0, 8, 16, 24). Data points show a decline for both strengths with statistical significance noted at weeks 16 and 24 for the higher dose compared to the lower dose.*
FDA Label Image

Figure A (D73584f8 B01b 4860 98b2 6528d9766e4d 11)

Figure A (D73584f8 B01b 4860 98b2 6528d9766e4d 11)
Illustration of the Rivastigmine Transdermal System components and packaging. It shows a sealed pouch labeled with the product name and manufacturer Northstar Rx LLC, containing one transdermal system. The patch is depicted with protective liners on both sides, an adhesive layer containing medicine, and an outside backing labeled accordingly.*
FDA Label Image

Figure B (D73584f8 B01b 4860 98b2 6528d9766e4d 12)

Figure B (D73584f8 B01b 4860 98b2 6528d9766e4d 12)
Illustration showing possible application sites for Rivastigmine patch on the human body. It depicts left or right upper arm, left or right side of chest, left or right upper back, and left or right lower back areas as locations for patch placement, indicated by shaded and striped rectangles on simplified human figures from side, front, and back views.*
FDA Label Image

Figure C (D73584f8 B01b 4860 98b2 6528d9766e4d 13)

Figure C (D73584f8 B01b 4860 98b2 6528d9766e4d 13)
Illustration showing a hand holding a Rivastigmine Transdermal System package being cut open with scissors as indicated by a dotted line. The package label displays the product name, usage instructions for transdermal administration, and the Northstar Rx LLC labeler name.*
FDA Label Image

Figure D (D73584f8 B01b 4860 98b2 6528d9766e4d 14)

Figure D (D73584f8 B01b 4860 98b2 6528d9766e4d 14)
Illustration showing hands peeling back the protective covering from a circular transdermal patch, demonstrating how to open the patch packaging for Rivastigmine.*
FDA Label Image

Figure E (D73584f8 B01b 4860 98b2 6528d9766e4d 15)

Figure E (D73584f8 B01b 4860 98b2 6528d9766e4d 15)
Illustration showing the application of a transdermal system patch with protective liners being peeled off by hands. Arrows indicate the protective liners and the sticky surface of the patch, which is intended for rivastigmine delivery as a transdermal system.*
FDA Label Image

Figure F (D73584f8 B01b 4860 98b2 6528d9766e4d 16)

Figure F (D73584f8 B01b 4860 98b2 6528d9766e4d 16)
An instructional illustration showing the application of a patch to the upper back of a person. One hand is holding the patch, while the other hand uses two fingers to press the patch onto the skin, indicating proper placement and adhesion technique.*
FDA Label Image

Figure G (D73584f8 B01b 4860 98b2 6528d9766e4d 17)

Figure G (D73584f8 B01b 4860 98b2 6528d9766e4d 17)
An illustration showing the back of a person with a hand positioned to apply or place an item on the upper back area near the shoulder blade. The image likely depicts proper placement or administration technique for a transdermal patch or topical application.*
FDA Label Image

Figure H (D73584f8 B01b 4860 98b2 6528d9766e4d 18)

Figure H (D73584f8 B01b 4860 98b2 6528d9766e4d 18)
An instructional illustration showing a person applying a patch to the upper chest area near the shoulder. One hand holds the patch while the other hand presses it firmly onto the skin with a circular motion indicated by an arrow.*
FDA Label Image

Figure I (D73584f8 B01b 4860 98b2 6528d9766e4d 19)

Figure I (D73584f8 B01b 4860 98b2 6528d9766e4d 19)
Instructional illustration for proper disposal of a Rivastigmine transdermal patch. It shows three steps: folding the sticky sides of the patch together, placing the folded patch into an empty pouch, and discarding it in the trash while keeping it away from children and pets.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 09)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 09)
Packaging label for Rivastigmine Transdermal System, each system delivering 4.6 mg/24 hours, manufactured for Northstar Rx LLC. It includes instructions for discarding the patch, storage information, and barcode details. The label states the box contains 30 systems for transdermal use only, with manufacturer Zydus Lifesciences Ltd. noted. The design includes dosage, warnings, and branding with Northstar logo.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 20)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 20)
Packaging label for Rivastigmine Transdermal System 9.5 mg/24 hours from Northstar Rx LLC. The label states it contains 30 systems for transdermal use only, manufactured by Zydus Lifesciences Ltd. Instructions for discarding the patch are provided on the inner panel. The design includes the NDC 16714-116-02 and highlights storage and usage details.*
FDA Label Image

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 21)

Rivastigmine Transdermal System (D73584f8 B01b 4860 98b2 6528d9766e4d 21)
Rivastigmine Transdermal System 13.3 mg/24 hours carton label shows a patch system for transdermal use only. The package contains 30 systems and highlights dosage strength and administration instructions. Manufactured for Northstar Rx LLC, with manufacturing by Zydus Lifesciences Ltd. Includes directions for safe patch disposal and storage information at 20° to 25°C.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.